Lataa...
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a...
Tallennettuna:
| Julkaisussa: | Mol Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718690/ https://ncbi.nlm.nih.gov/pubmed/33276788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01290-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|